Opioid use surrounding diagnosis and follow-up in patients with ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis: Results from US claims databases

• Published in: Clinical rheumatology 2024-06, Vol.43 (6), p.1897-1907
• Main Authors: Sheahan, Anna, Anjohrin, Suzanne, Suruki, Robert, Stark, Jeffrey L., Sloan, Victor S.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Analgesics, Opioid - therapeutic use; Ankylosing spondylitis; Arthritis, Psoriatic - diagnosis; Arthritis, Psoriatic - drug therapy; Arthritis, Rheumatoid - diagnosis; Arthritis, Rheumatoid - drug therapy; Arthritis, Rheumatoid - epidemiology; Autoimmune diseases; Databases, Factual; Diagnosis; Discordance; Disease; Female; Follow-Up Studies; Humans; Male; Medicaid; Medicaid - statistics & numerical data; Medicine; Medicine & Public Health; Middle Aged; Narcotics; Opioids; Original; Original Article; Patients; Prevalence; Psoriatic arthritis; Rheumatoid arthritis; Rheumatology; Spondylitis, Ankylosing - diagnosis; Spondylitis, Ankylosing - drug therapy; United States; Young Adult
• ISSN: 0770-3198; 1434-9949; 1434-9949
• DOI: 10.1007/s10067-024-06945-0

Objective To describe patients’ use of opioids in the year preceding and year following new diagnosis of ankylosing spondylitis (AS), psoriatic arthritis (PsA), or rheumatoid arthritis (RA), compared with patients without the/se diseases. Methods This study used US IBM ® MarketScan ® Commercial Claims and Encounters (CCAE) and Medicaid data and included three cohorts, comprised of incident cases of AS, PsA, or RA (2010–2017). Three matched comparator patients (without the incident disease) were selected for each patient within the disease cohort. Opioid use and appropriate treatment exposure (as defined by US guideline recommendations) in the 12-month baseline and follow-up periods were evaluated using descriptive analyses. Results Prevalence of claims for opioids was higher for disease cohorts vs. comparators in CCAE; 36.4% of patients with AS, 29.5% with PsA, and 44.4% with RA did not have any claim for guideline-appropriate therapy in follow-up. Prevalence of claims for opioids was also higher for disease cohorts vs. comparators in Medicaid; 30.6% of patients with AS, 36.6% with PsA, and 65.4% with RA did not have any claim for guideline-appropriate therapy in follow-up. Conclusions In patients with AS, PsA, or RA, there was high reliance on opioids at and around the time of diagnosis. Significant proportions of patients were not on appropriate treatment as defined by professional society post-diagnosis guidelines; this discordance between actual patient therapies and treatment recommendations may suggest a need for better awareness of appropriate pain management and treatment strategies in rheumatic diseases. Key Points • This study analysed opioid use among patients with ankylosing spondylitis (AS), psoriatic arthritis (PsA), or rheumatoid arthritis (RA), and adds to current knowledge by expanding beyond assessment of opioid use at diagnosis, to the year before and after diagnosis . • Opioid use was found to be highly prevalent in AS, PsA, and RA in the year prior to diagnosis and, interestingly, was still seen during the year after diagnosis . • Opioids are neither disease modifying, nor a targeted/recommended treatment for chronic autoimmune diseases. In addition to their association with significant economic costs, opioids are potentially hazardous and are not better than alternative treatments with superior safety profiles . • The reasons behind opioid prescribing patterns should be explored further to support movement to targeted therapies .